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Background/aim: This study compared TRPM2 and TRPM7 ion channel gene expression and immunohistochemical staining in
endometrial hyperplasia and endometrium adenocarcinoma.
Materials and methods: Sections were taken from paraffin blocks of 120 patients who were divided into 6 groups as follows: G1 (n =
20), proliferative endometrium (PE); G2 (n = 20), EH without atypia; G3 (n = 20), EH with atypia; G4 (n = 20), stage 1A, grade 1 EC;
G5 (n = 20), stage 1A, grade 2 EC; and G6 (n = 20), stage 1A, grade 3 EC. TRPM2 and TRPM7 genes were analyzed with qRT-PCR in
paraffin-embedded tissue samples. Under light microscopy, TRPM2 and TRPM7 immunostaining scores of the samples taken from
polylysine slides were evaluated.
Results: Compared to G1, TRPM2 mRNA gene expression was significantly downregulated in G3 and G5. TRPM2 immunoreactivity
scores were similar in all groups. TRPM7 mRNA gene expression was significantly downregulated in G2, G3, and G6 when compared to
G1. TRPM7 immunoreactivity scores were similar in G1, G2, and G3, but significantly decreased in G4, G5, and G6.
Conclusion: Reduction in TRPM7 ion channel activity may be a progression marker for endometrial hyperplasia regardless of the
atypical criteria.
Key words: TRPM2, TRPM7, endometrial hyperplasia, endometrioid adenocarcinoma

1. Introduction
Endometrial hyperplasia (EH) is a pathologic condition
characterized by hyperplastic changes in the endometrial
glandular and stromal structures covering the uterine
cavity (1). Chronic exposure to estrogens not met by
progesterone is considered as a key component in the
development of EH and endometrial carcinoma (EC)
(2). The important risk factors for EH development are
obesity, unbalanced estrogen therapy, tamoxifen therapy,
polycystic ovary syndrome, and nulliparity (3). EH is
the precursor for endometrioid adenocarcinoma of the
endometrium. According to classical classification, the
progression of carcinoma is 0%–3% in simple hyperplasia
without atypia, 0%–8% in simple atypical hyperplasia, and
9%–29% in complex atypical hyperplasia (4,5).
EC is the most common gynecological cancer
observed in developed countries (6). EC has two major
types: endometrioid carcinoma (type 1) due to hormonal

imbalance and serous carcinoma (type 2) not associated
with estrogen (7). While EC constitutes 3.6% of all new
cancer cases in 2016, it is responsible for 1.8% of all cancer
deaths in the United States (8). Moreover, as risk factors
including obesity and progressive age become more
common, the incidence is likely to increase. Fortunately,
based on signs and symptoms (such as abnormal uterine
bleeding), an early stage (stage I) diagnosis can be made in
many patients (about 75%) (9).
Tumor progression occurs as a result of changes in
physiological processes such as cell proliferation, apoptosis,
migration, invasion, and angiogenesis. These processes
are under the control of the calcium homeostasis and
transient receptor potential (TRP) cation channels (10).
Ion channels and significant TRP channels are involved in
many physiological processes. These channels have been
shown to be associated with some serious diseases, such as
cancer. During the onset and progression of cancer, altered
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expression of one or more TRP proteins is of importance
(11). Excessive TRPM2 levels in cancer cells may have an
enzymatic function in relation to cell proliferation (12).
Vascular endothelial growth factor (VEGF), basal
fibroblast growth factor (bFGF), and platelet-derived
growth factor (PDGF) stimulate angiogenesis by
increasing the proliferation and migration of endothelial
cells. These angiogenic factors may increase intracellular
Ca2+ concentration in endothelial cells through the
activation of plasma membrane receptors and the release
of Ca2+ from the endoplasmic reticulum. This also leads
to activation of Ca2+ channels in the plasma membrane.
Several studies have emphasized the importance of TRP
channel-mediated Ca2+ signals in the angiogenesis process
(13).
In previous studies, TRPM2 has been shown to alter
endothelial cell function in response to oxidative stress.
Blocking TRPM7 has been shown to cause increased
growth and proliferation in addition to causing increased
expression of nitric oxide synthase and nitric oxide
production (14).
TRPM7 plays a role in angiogenesis and oxidative
stress-related cell death (15). Recent TRPM7 studies on
ovarian cancer have shown that TRPM7 is necessary for
cancer cell growth, migration, and invasion (16).
The purpose of the present study was to investigate
the activity of TRPM2 and TRPM7 ion channels due to
their close relationship with proliferation and migration
mechanisms in endometrial hyperplasia and early stage
endometrial cancer.
2. Materials and methods
2.1. Patient selection
In this retrospective study, qRT-PCR analysis and
immunohistochemical staining were performed for
paraffin-embedded archive tissues of patients with
proliferative endometrium (PE), EH, and early stage EC.
Approval to conduct the study was obtained from the local
ethics committee of Fırat University (Dated 20.04.2017,
Session No: 07, Decision No: 01). Patients diagnosed
with PE, EH, and endometrial adenocarcinoma (EC)
with hysterectomy between 2007 and 2017 in the Fırat
University Faculty of Medicine’s Obstetrics and Gynecology
Department were included in the study. The paraffin
blocks of 120 patients were resectioned in the pathology
clinic. In this study, because it was aimed to investigate
the importance of ion channels in the progression from
PE to EH and EC, early stage EC cases were selected in the
endometrial carcinoma group. A total of 120 cases were
divided into 6 groups: G1 (n = 20), PE group; G2 (n = 20),
EH without atypia; G3 (n = 20), EH with atypia; G4 (n =
20), stage 1A according to FIGO staging (tumor size <2
cm, myometrial invasion <1/2), grade 1 EC; G5 (n = 20),
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stage 1A, grade 2 EC; G6 (n = 20), stage 1A, grade 3 EC.
2.2. RNA isolation, complementary DNA (cDNA) synthesis, and quantitative real-time PCR (qRT-PCR) analysis
For RNA isolation from the supplied paraffin blocks,
sections of 0.2 mm in thickness were taken, stacked in
Eppendorf tubes, and stored at –80 °C for isolation. The
RNA isolation from the paraffin blocks was performed
using TRIzol. For paraffin melting, sections of 20 µm
were placed in Eppendorf tubes and kept for 1 h in a heat
block at 65 °C. For the removal of the paraffin, 1000 µL
of xylol (heated at 65 °C in an incubator) was placed in
Eppendorf tubes, and after 5 min of incubation at 65 °C,
centrifugation was performed at 14,000 rpm for 2 min.
After the centrifugation, the supernatant was removed. The
processes after the xylol addition were repeated 3 times. By
placing 1000 µL of 100% ethanol into the Eppendorf tubes,
vortexing was done. After holding this mixture for 15 min
in the incubator at 37 °C, centrifugation was performed at
14,000 rpm for 2 min and the supernatant was removed.
By placing 1000 µL of 70% ethanol into the Eppendorf
tubes, vortexing was done. It was held for 15 min at 37
°C in the incubator. Centrifugation was performed at
14,000 rpm for 2 min and the supernatant was removed.
By placing 1000 µL of 50% ethanol into the Eppendorf
tubes, vortexing was done. It was held for 15 min at 37 °C
in the incubator and then centrifugation was performed at
14,000 rpm for 2 min and the supernatant was removed.
After that, 750 µL of TRIzol, 60 µL of proteinase K, and
2 µL of RNase inhibitor were added to the Eppendorf
tubes and they were held for 1 night in a shaking water
bath set to 60 °C. Samples were expected to fall to room
temperature. Chloroform (300 µL) was then added to the
Eppendorf tubes and vortexing was performed for 15 s.
Centrifugation was performed at 4 °C and 20,000 rpm for
20 min and the phase remaining on the top was transferred
to new tubes. Isopropyl alcohol (800 µL) was then added
to them, and after shaking, the tubes were held for 1 night
at room temperature. Centrifugation was performed at 4
°C and 13,500 rpm for 10 min and the upper phase was
removed. Washing was done with 75% ethyl alcohol. After
shaking, centrifugation was performed at 4 °C and 7500
rpm for 5 min and then tubes were held open for 10 min to
allow the release of ethanol. Based on the size of the white
RNA pellet remaining at the bottom, DNase, RNase, and
pyrogen-free water were added.
Total RNA isolation from tissue samples was performed
using TRI Reagent (BioShop, Canada) and the RNA quantity
and quality were determined by BioSpec-nano (Shimadzu,
Japan). Complementary DNA synthesis was carried
out in accordance with the protocol of a High-Capacity
cDNA Reverse Transcription Kit (Applied Biosystems,
USA) in a thermal cycler (Veriti 96-Well Thermal Cycler,
Applied Biosystems). With the obtained complementary
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DNAs, gene expression levels were determined using an
Applied Biosystems 7500 Real Time PCR instrument for
transient receptor potential cation channel subfamily M
member 2 (TRPM2) and TRPM7 (rabbit anti-TRPM2
antibody, Ab101738, and goat anti-TRPM7 antibody, ab
729, Abcam, Cambridge, UK, Catalog No. QT01609965,
QIAGEN). By using EvaGreen 2X qPCR MasterMix
(abm), the mixture required for the determination of
gene expressions was prepared according to the relevant
protocol. Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) (Cat. No. QT00079247, QIAGEN, USA) was
used as the control gene (housekeeping). Calculation of
differences between gene expressions was performed by
the 2–ΔΔCT method.
2.3. Immunohistochemical evaluation
The sections taken from paraffin blocks of 4–6 µm in
thickness were taken into polylysine slides. For antigen
retrieval, the deparaffinized tissues were passed through
a graded alcohol series and boiled in a microwave (750
W) for 7 + 5 min at pH 6 in citrate buffer solution.
After boiling, the tissues that were left to cool at room
temperature for about 20 min were incubated for 5 min
with hydrogen peroxide block solution in order to prevent
endogenous peroxidase activity after washing for 3 × 5
min with phosphate buffered saline (PBS) solution [PBS
(10 mM Na2HPO4, 10 mM KH2PO4, 0.9 g NaCl/100 mL,
pH 7.4), P4417, Sigma-Aldrich, USA), TA-125-HP, Lab
Vision Corporation, USA].
After washing with PBS for 3 × 5 min, to be able to
block the background stain, a solution of Ultra V Block
(TA-125-UB, Lab Vision Corporation) was applied to the
tissues for 5 min and then they were incubated with 1/200
diluted primary antibodies (rabbit anti-TRPM2 antibody,
Ab101738, and goat anti-TRPM7 antibody, ab 729,
Abcam) for 60 min at room temperature. The tissues were
washed with PBS for 3 × 5 min after the application of the
primary antibody and then washed twice with secondary
antibodies (biotinylated goat anti-polyvalent, TP-125-BN,
Lab Vision Corporation, and donkey anti-goat, sc-2042,
Santa Cruz Biotechnology, USA) for 30 min at room
temperature in a humidified environment. The tissues
were washed with PBS for 3 × 5 min after the application
of the secondary antibody and incubated in a humidified
environment for 30 min with streptavidin-peroxidase (TS125-HR, Lab Vision Corporation), and then they were put
into PBS. After a solution of 3-amino-9-ethylcarbazole
(AEC) substrate + AEC chromogen (AEC substrate, TA015 and HAS, AEC chromogen, TA-002-HAC, Lab Vision
Corporation) was added to the tissues and an image signal
was obtained with a light microscope, the tissues were
simultaneously washed with PBS. Rabbit IgG was used for
the negative control. Tissues counterstained with Mayer’s
hematoxylin were treated with PBS and distilled water and

covered with appropriate closure solution (Large Volume
Vision Mount, TA-125-UG, Lab Vision Corporation).
The preparations were evaluated and photographed with
a Leica DM500 microscope (Leica DFC295). Under light
microscopy, based on the extent of immunoreactivity (0.1:
<25%, 0.4: 26%–50%, 0.6: 51%–75%, 0.9: 76%–100%) and
the intensity (0: no, + 0.5: very little, + 1: less, + 2: moderate,
+ 3: severe), the histoscore was determined (histoscore =
extensity × intensity) (17).
2.4. Statistical analysis
All analyses were performed with SPSS 22.0 (IBM Corp.,
Armonk, NY, USA). The data obtained from qRT-PCR
evaluations were determined as mean ± standard deviation.
Immunohistochemistry scores were calculated as
median and minimum–maximum values. Whether or
not the numerical measurements ensured the normality
(normal distribution) assumption was tested by the
Kolmogorov–Smirnov test. For numerical measurements
that did not show normal distribution, the Mann–Whitney
U test was used for the comparison between the two
groups. The Kruskal–Wallis test was used for the general
comparison between more than two groups. In such cases,
for the values that were found significant, Bonferroni
correction was performed for the binary comparisons
of the groups. P < 0.008 was accepted as statistically
significant.
3. Results
3.1. Genetic findings
In terms of gene expression of TRPM2 mRNA between the
groups, there was no significant difference between G2 (P
= 0.037), G4 (P = 0.047), and G6 (P = 1.00) compared to
G1. When compared to G1, a significant downregulation
was observed between G3 (P = 0.003) and G5 (P = 0.001).
In addition, in within-group comparisons, a statistically
significant upregulation was observed in G6 (P = 0.008)
when compared to G2. TRPM2 gene expression did not
show any significant difference in other within-group
comparisons (Figure 1).
In terms of gene expression of TRPM7 mRNA between
the groups, a statistically significant downregulation was
observed in G2 (P = 0.003), G3 (P = 0.002), and G6 (P
= 0.000) compared to G1. There was no significant
difference between G1 and G4 (P = 0.01) and G5 (P =
0.012). In addition, in terms of TRPM7 gene expression,
no significant difference was observed in the other withingroup comparisons (Figure 1).
3.2. Immunohistochemical findings
Related to TRPM2 immunoreactivity, in the betweengroup comparison, there was no significant difference for
G1 [0.23 (0.1–0.8)], G2 [0.30 (0.1–0)], G3 [0.32 (0.1–0.9)],
G4 [0.35 (0.1–1.2)], G5 [0.31 (0.1–0.6)], and G6 [0.34
(0.1–0.8)] (P = 0.1997) (Table; Figure 2).
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Table. TRPM2 and TRPM7 immunoreactivity histoscores
(extensity × intensity) in all groups.

Figure 1. RT-PCR results for TRPM2 and TRPM7. a: Significant
downregulation of TRPM2 gene expression is shown in G3
and G5 when compared with G1. b: Statistically significant
upregulation of TRPM2 gene expression was observed in G6
when compared to G2. c: Significant downregulation of TRPM7
gene expression is shown in G2, G3, and G6 when compared
with G1. G1 = Proliferative endometrium; G2 = endometrial
hyperplasia without atypia; G3 = endometrial hyperplasia with
atypia; G4 = stage 1A, grade 1 endometrium adenocarcinoma;
G5 = stage 1A, grade 2 endometrium adenocarcinoma; G6 =
stage 1A, grade 3 endometrium adenocarcinoma.

Related to TRPM7 immunoreactivity, in the betweengroup comparison, there was no significant difference for
the comparison of G1 [0.66 (0.1–2.7)], G2 [0.61 (0.1–1.2)],
and G3 [0.65 (0.1–1.8)] (P > 0.008). When compared with
G1 [0.66 (0.1–2.7)], the TRPM7 immunoreactivity had
significantly decreased in G4 [0.18 (0.0–0.5)], G5 [0.19
(0.0–0.5)], and G6 [0.17 (0.0–0.4)] (P < 0.001) (Table;
Figure 3).
4. Discussion
In this study, mRNA gene expression and
immunohistochemical staining scores of TRPM2 and
TRPM7 were assessed in the course of EH up to the
early stage of EC. The results of the study suggest that a
significant reduction in TRPM7 mRNA downregulation
and immunoreactivity score, especially in the prognosis of
EH, may be a progression marker.
Biomarkers are defined as properties “that can be
measured and evaluated objectively as indicators of normal
biological and pathogenic processes or pharmacological
responses to therapeutic intervention” (18). The best
molecular biomarker is a biomarker that is reliable and
reproducible and can allow the differentiation of normal/
benign, premalignant, and malignant endometrium to
ensure that the transition between these three groups is
demonstrated or predicted. Until now, there has not been
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Groups

TRPM2

TRPM7

G1

0.23 (0.1–0.8)

0.66 (0.1–2.7)

G2

0.30 (0.1–0.6)

0.61 (0.1–1.2)

G3

0.32 (0.1–0.9)

0.65 (0.1–1.8)

G4

0.35 (0.1–1.2)

0.18 (0.0–0.5)a

G5

0.31 (0.1–0.6)

0.19 (0.0–0.5)a

G6

0.34 (0.1–0.8)

0.17 (0.0–0.4)a

P-value

<0.197

<0.001

a
: When compared with G1, the TRPM7 immunoreactivity had
significantly decreased in G4, G5, and G6 (P < 0.001).
G1 = Proliferative endometrium; G2 = endometrial hyperplasia
without atypia; G3 = endometrial hyperplasia with atypia; G4 =
stage 1A, grade 1 endometrium adenocarcinoma; G5 = stage 1A,
grade 2 endometrium adenocarcinoma; G6 = stage 1A, grade 3
endometrium adenocarcinoma.

a single candidate that fulfills this role and studies are
ongoing. A variety of immunohistochemical biomarkers
have been investigated in the literature to help in the
diagnosis and classification of EH and to predict the
likelihood of transition from EH to EC (19). For example,
in their study, Horrée et al. (20) showed that progesterone
receptor-B (PR-B) expression was higher in women with
atypical hyperplasia with 90% reduced lesion persistence/
progression risk. Erkanli et al. (21) showed statistically
significant COX-2 overexpression in EH and EC cases
compared with PE. Horrée et al. (22) determined that
almost all negative cells in inactive endometrium showed
increasing expression of p53 in EH where only a few cells
were positive and that the highest gene expression was
seen in endothelial cells. Kurdoğlu et al. (23) showed
a gradual increase in lamin receptor-1 expression in
epithelial basal membranes of hyperplastic endometrium,
with atypia or not, based on the progression of the disease.
They also showed that it may play an important role in the
transition from premalignant status to endometrial lesions
in malignant conditions.
The TRP superfamily is a representative of an alliance
composed of mostly nonselective Ca2+-permeable cation
channels that respond to a wide range of chemical and
physical stimuli (24) and represent the potential key players
in intercellular signaling between uterine epithelium and
stromal cells. However, available information related to
the distribution of TRP channels in human endometrial
epithelial and stromal cells is insufficient (25). Interestingly,
the characteristic mRNA expression profile of some TRP
channels throughout the menstrual cycle may suggest

YALÇIN et al. / Turk J Med Sci

Figure 2. TRPM2 immunostaining is similar in all groups (red arrow): a) G1, b) G2, c) G3, d) G4, e) G5, f) G6. G1 = Proliferative
endometrium; G2 = endometrial hyperplasia without atypia; G3 = endometrial hyperplasia with atypia; G4 = stage 1A, grade 1
endometrium adenocarcinoma; G5 = stage 1A, grade 2 endometrium adenocarcinoma; G6 = stage 1A, grade 3 endometrium
adenocarcinoma.

that these TRP channels are regulated by sex hormones
such as estrogen and progesterone. Regulation of TRP
mRNA by steroid hormones in endometrial cells has been
previously reported for TRPV6 and TRPC1 (26,27). TRP
channels are expressed differentially in different cancer
types. It has been reported that TRPM2 is expressed in
many cancer types such as bladder, breast, lung, liver,
head, and neck cancers (28). Although the mechanisms
regulating its expression are not well known, TRPM2 has
been shown to have many methylation sites capable of
modulating malignancy (29). In our study, it was observed
that TRPM2 miRNA gene expression was significantly
downregulated in atypia EH and grade 2 EC compared
to PE, and that there was a statistically significant
upregulation in grade 3 EC compared to EH without
atypia; however, there was no significant difference in
immunoreactivity staining scores between the groups.
The reason why the TRPM2 miRNA downregulation
cannot be demonstrated immunohistochemically may be
that the gene expression is not at a level that can produce
immunohistochemical differences in the amount of
suppressed protein. The discrepancy between PCR results
and immunohistochemistry results can be explained as
follows: in general, sensitivity and specificity increase
with PCR methods compared to immunohistochemistry.
However, the correlation between these two methods is
weak. Each of them performs different analyses in terms

of the characteristics of cell biology. The purpose of RTPCR is to confirm whether the protein-producing gene is
active or not through mRNA analysis. On the other hand,
immunohistochemistry confirms the presence of protein.
The morphology is maintained in the immunohistochemistry
procedure and allows recognition of immunostaining
heterogeneity and confirmation that the defined positivity
is present in tumor cells. On the other hand, the RTPCR technique is a nonmorphological technique and the
contamination of tumor mRNA with normal tissue can affect
the results and may cause inconsistencies between the two
techniques. As a result, the expression at mRNA and protein
levels may not always be synchronized (30,31). In their
study, Hiroi et al. (29) showed that the TRPM2 gene was an
estrogen-dependent gene in cultured endometrial stromal
cells. They also showed that there was no increase in TRPM2
mRNA expression in the medium and late endometrial
proliferative phase where estrogen was the highest. They
considered that other regulatory factors could be effective
on the proliferative endometrial phase of in vivo mRNA
transcription in the human endometrium and found that
TRPM2 mRNA expression significantly increased in the
late secretory phase. In cultured endometrial stromal
cells, estrogen and progesterone treatment increased
the TRPM2 mRNA expression. In a study conducted on
rats, Ahn et al. (32) showed that TRPM2 mRNA levels
increased significantly in proestrus and returned to basal
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Figure 3. TRPM7 immunostaining is shown as similar in G1, G2, and G3. Decreased TRPM7 immunostaining is shown in G4, G5, and
G6 relative to G1 (red arrows). a) G1, b) G2, c) G3, d) G4, e) G5, f) G6. G1 = Proliferative endometrium; G2 = endometrial hyperplasia
without atypia; G3 = endometrial hyperplasia with atypia; G4 = stage 1A, grade 1 endometrium adenocarcinoma; G5 = stage 1A, grade
2 endometrium adenocarcinoma; G6 = stage 1A, grade 3 endometrium adenocarcinoma.

levels in metestrus and to previous levels in diestrus.
Another reason for the downregulation of the TRPM2
mRNA expressions in our grade 2 EC and EH with atypia
groups and the upregulation in grade 3 EC compared to EH
without atypia may be the fact that, as mentioned above,
estrogen is different in its effects on the endometrium at
different periods and many factors coexist in vivo in the
etiopathogenesis of carcinoma. More extensive research
is needed in this regard. Increased evidence has shown
that TRPM7 members play an important role in cellular
processes, embryonic development, and human disease,
especially in cancer. Accumulated data emphasize the
potential importance of TRPM7 as a molecular biomarker
and therapeutic target in human malignancies (33–36).
TRPM7 is both an ion channel and a kinase protein that
regulates different cellular processes in many solid tumor
types. However, EC has not been evaluated yet. Nakashima
et al. (37) demonstrated that immunohistochemical and
siRNA suppression of TRPM7 promotes proliferation,
migration, and invasion in esophageal squamous cell
carcinoma. Conversely, Rybarczk et al. (38) reported that
high TRPM7 levels were associated with poor prognosis in
ductal adenocarcinoma of the pancreas. Wang et al. (16)
suggested that overexpression of TRPM7 in ovarian cancer
is associated with poor prognosis. In this study, we also
showed that TRPM7 miRNA was downregulated in the
EH (with atypia or without atypia) and grade 3 EC groups
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compared to the PE group. Immunohistochemically, we
found only a significant decrease in the EC groups (grades
1, 2, and 3). However, we could not find any significant
difference between grades 1, 2, and 3 in stage 1A EC. When
we compared our genetic results and immunohistochemical
results, we observed that there was a similarity only in the
grade 3 EC group.
TRPM7 has been reported to play a critical role in the
transition from stagnation to proliferation (39). Throughout
the menstrual cycle, stromal cells go to proliferation and
differentiation. It has been shown that TRPM7 plays a critical
role in proliferating cells and gene expression decreases in
differentiated cells (40,41). Sahni and Scharenberg (42)
reported that the growth rates of TRPM7-deficient cells are
rapidly downregulated, which leads to a secondary arrest
in proliferation. On the other hand, the effect of TRPM7
on cell survival and growth has been investigated and
silencing of TRPM7 has been shown to cause growth and
proliferation for some cell types such as human umbilical
cord endothelial cells (14). Although TRPM7 mRNA
gene expressions were significantly downregulated in EH
(with or without atypia), the TRPM7 immunoreactivity
score in our study was not different from the PE group
even in the atypical EH group. Thus, we can say that the
different mechanisms that play a role in cancer biology may
contribute to the reduction of TRPM7 immunoreactivity
in our EC groups. Nakashima et al. (37) also showed
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that TRPM7 downregulation significantly increased cell
proliferation, migration, and invasion. This suggests that
the significant reduction in TRPM7 immunoreactivity in
our EC groups may be a consequence of the proliferation
and the increase in invasion compared to EH groups. The
fact that the TRPM7 gene expression in grade 3 EC is
significantly downregulated compared to grade 1 and grade
2 can also provide insight for future studies by indicating
that TRPM7 may be a sign of progress in EC.
The main limitation of our study is that it is a retrospective
study with a limited number of cases. It may also have been
more valuable to examine cases progressing to stage 1A EC
by monitoring EH cases in the long term. However, it is

clear that this would not be ethical. On the other hand, the
fact that TRPM2 and TRPM7 have been studied for the first
time in EH and EC as progression markers can be shown as
the strength of our study.
In conclusion, in early stage endometrial cancers,
a significant reduction in TRPM7 ion channel activity
relative to endometrial hyperplasia may be a progression
marker for endometrial hyperplasia independently of the
atypia criteria.
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